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A B S T R A C T   
Some cannabinoids showed anti-inflammatory and antifibrotic activities. EHP-101 is an oral lipidic formulation 
of the novel non-psychotropic cannabidiol aminoquinone VCE-004.8, which showed antifibrotic activity in 
murine models of systemic sclerosis induced by bleomycin. We herein examined the effect of EHP-101 on cardiac 
and other organ fibrosis in a mouse model induced by Angiotensin II. VCE-004.8 inhibited TGFβ- and Ang II- 
induced myofibroblast differentiation in cardiac fibroblasts detected by α-SMA expression. VCE-004.8 also 
inhibited Ang II-induced ERK 1 + 2 phosphorylation, NFAT activation and mRNA expression of IL1β, IL6, Col1A2 
and CCL2 in cardiac fibroblasts. Mice infused with Ang II resulted in collagen accumulation in left ventricle, 
aortic, dermal, renal and pulmonary tissues; oral administration of EHP-101, Ajulemic acid and Losartan 
improved these phenotypes. In myocardial tissue, Ang II induced infiltration of T cells and macrophages together 
with the accumulation of collagen and Tenascin C; those were all reduced by either EHP-101 or Losartan 
treatment. Cardiac tissue RNA-Seq analyses revealed a similar transcriptomic signature for both treatments for 
inflammatory and fibrotic pathways. However, the gene set enrichment analysis comparing data from EHP-101 
vs Losartan showed specific hallmarks modified only by EHP-101. Specifically, EHP-101 inhibited the expression 
of genes such as CDK1, TOP2A and MKi67 that are regulated to the E2 factor family of transcription factors. This 
study suggests that the oral administration of EHP-101 prevents and inhibits cardiac inflammation and fibrosis. 
Furthermore, EHP-101 inhibits renal, pulmonary and dermal fibrosis. EHP-101 could offer new opportunities in 
the treatment of cardiac fibrosis and other fibrotic diseases.   
1. Introduction 
Cardiovascular diseases are nowadays the main cause of mortality in 
the world [1]. Among them, ischemic heart disease and other conditions 
such as hypertensive heart disease, idiopathic dilated cardiomyopathy 
and diabetic hypertrophic cardiomyopathy may lead to endomyocardial 
fibrosis, one of the psychopathological events that causes heart failure 
[2–4]. 
Cardiac fibrosis is produced by the accumulation of extracellular 
matrix (ECM) in the myocardium. The increase of ECM in the myocar-
dium followed by extensive fibrotic remodeling in the ventricle abol-
ishes cardiac contractility and it is associated with the loss of a large 
number of cardiomyocytes ultimately leading to replacement of dead 
myocardium with a collagen-based scar [5]. The expression of several 
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pro-inflammatory cytokines and pro-fibrotic factors induces differenti-
ation of variety of progenitor lineages including endothelial cells and 
resident fibroblast to myofibroblast in a process known as endothelial to 
mesenchymal transition. Myofibroblasts show larger proliferative, con-
tractile, migratory and collagen producing abilities [6]. The activation 
of inflammation together with the transformation to myofibroblasts 
produce a high accumulation and synthesis of ECM proteins; the 
collagen deposition in the myocardium impairs cardiac function and 
finally leads to heart failure [6]. 
The renin-angiotensin system (RAS) is the regulatory system of car-
diovascular and renal function and its deregulation exerts potent 
atherosclerotic, inflammatory and fibrotic effects.[7] Angiotensin is the 
central effector of RAS. It is formed from the enzymatic cleavage of 
angiotensinogen to Ang I by the aspartyl protease renin. Then, the 
angiotensin converting enzyme (ACE) converts Ang I to Ang II. [8] Ang 
II exerts biological activities by binding to the Ang receptor subtypes, 
Ang receptor 1 (AT1) and Ang receptor 2 (AT2) [8]. Most of the effects of 
Ang II are mediated by binding to AT1, which is widely present in many 
tissues and organs, including skin, lung, kidney and heart [9–12]. 
Moreover, this peptide hormone is a potent proinflammatory agent that 
modulates immune responses, including T-cell proliferation and differ-
entiation of monocytes into macrophages [13,14]. It is known that Ang 
II has involved in the evolution of myocardial fibrosis. Indeed, Ang II has 
been described to be a potent pro-fibrotic molecule [15,16]. In fact, 
recent studies has seen increased serum levels of Ang II in patients with 
cardiovascular diseases that are associated with myocardial fibrosis, 
including hypertension cardiac hypertrophy, atherosclerosis and heart 
failure [15,17,18]. 
Following cardiac injury, the immune system plays an important role 
in repair and regeneration and is implicated in the initiation and regu-
lation of the cardiac fibrotic process including vascular damage [19]. 
The inflammation is also involved in the transition of cardiac fibroblasts 
to myofibroblasts, the hallmark of the fibrotic process. A crosstalk be-
tween fibroblasts and immune cells is a key step in triggering cardiac 
fibrosis. Indeed, T cells coordinate and mediate various immune cells 
activities, including monocytes and macrophages, which are enrolled to 
the site of the damage contributing to cardiac fibrosis [20]. The excess 
accumulation of collagen is not only attributed to the myofibroblasts but 
also macrophages that are directly involved in the deposition of collagen 
fibers in the myocardium [21]. Overall, the extent of inflammation 
significantly correlates to the severity of heart failure. 
Several lines of evidence have shown that the peroxisome 
proliferator-activated receptor-γ (PPARγ) and the canonical cannabinoid 
receptors 1(CB1R) and 2 (CB2R) are promising targets for the develop-
ment of new pharmacological therapies for the treatment of fibrotic 
diseases. 
It has been described that PPARγ ligand agonists reduce oxidative 
stress and inflammation and as a consequence, may be of therapeutic 
interest for cardiac fibrosis and to improve vascular endothelial function 
[22,23]. CB1R and CB2R have opposite roles in fibrotic diseases, while 
activation of CB1R is profibrotic, the activation of CB2R is anti-fibrotic in 
several animal models of fibrotic diseases [24,25]. 
Previously, we have proven the ability of VCE-004.8, a non- 
psychotropic aminoquinone derivative synthetic cannabidiol (CBD) 
acting as a dual agonist of CB2R and PPARγ, thereby avoiding 
bleomycin-induced fibrosis [25]. VCE-004.8 inhibited TGFβ-induced 
Col1A2 gene transcription, collagen synthesis and TGFβ-mediated 
myofibroblast differentiation [25]. EHP-101 is a lipidic formulation of 
VCE-004.8 for oral delivery that alleviated bleomycin-induced skin and 
lung fibrosis. EHP-101 also prevented skin vascular disruption induced 
by bleomycin and RNAseq analysis showed a clear effect on the in-
flammatory and epithelial-mesenchymal transition transcriptomic sig-
natures [26,27] completed a Phase I clinical study (clinicaltrial.gov: 
NCT03745001) and is now under Phase II in SSc patients (ClinicalTrials. 
gov: NCT04166552). In the present study we show how this formulation 
prevents Ang-II-induced inflammation and fibrosis in the heart as well as 
in other organs. 
2. Material and methods 
2.1. Cell lines and reagents 
Immortalized primary human cardiac fibroblasts (hICF) with SV40 
Large T antigen were purchased from Innoprot SL (Derio, Spain) and 
cultured in low passages (< 5 passages). The cells were maintained in a 
humidified atmosphere at 37 ◦C containing 5% CO2, 10% fetal bovine 
serum (FBS) and 1% (v/v) penicillin/streptomycin in Fibroblast 
Medium-2 (P60108-2, Innoprot, Derio, Spain). Ang II was purchased 
from Sigma-Aldrich Co (A9525, Sigma, Madrid, Spain) and TGFβ 
(Transforming Growth Factor-β)-1 (10 ng/ml) was obtained from 
ImmunoTools GmbH (Friesoythe, Germany). Ajulemic acid (AjA) 
was synthesized as described and its purity was >95%. [28] EHP- 
101 is a lipidic formulation of VCE-004.8 [(1′R,6′R)− 3- 
(Benzylamine)− 6-hydroxy-3′-methyl-4-pentyl-6′-(prop-1-en-2-yl) [1, 
1′bi(cyclo-hexane)]− 2′,3,6-triene-2,5-dione)] [26]. 
2.2. Luciferase assays 
hICF cells were transiently transfected for 24 h with the Gal4-Luc 
reporter plasmid (which includes five Gal4 DNA binding sites fused to 
the luciferase gene) and the Gal4-NFAT1–415 plasmid for 24 h using Roti- 
Fect (Carl Roth GmbH & Co. KG, Karlsruhe, Germany). Then cells were 
stimulated for 6 h as indicated. Luciferase activity in the cell lysates was 
measured as described previously [29] and the specific transactivation 
expressed as a percentage of activation relative to control. 
2.3. Western blots 
Cells were preincubated with VCE-004.8, treated with Ang II for 30 
min, washed with PBS and proteins extracted in 50 μL of lysis buffer [50 
mM Tris-HCl pH 7.5, 150 mM NaCl, 1% (v/v) NP-40, 10% (v/v) glycerol, 
10 mM NaF, 1 mM Na3VO4, aprotinin (10 μg/ml), leupeptine (10 μg/ 
ml), pepstatin (1 μg/ml) and 1 mM PMSF saturated]. Separated proteins 
in 10% SDS/PAGE gels were transferred to PVDF membranes and 
blocked in TBS solution containing 0.1% Tween 20% and 5% bovine 
serum albumin (BSA) for 1 h at room temperature. Immunodetection of 
specific proteins was carried out by incubation with primary antibodies 
against p-ERK (1:1000; # 4695 Cell Signaling Technology), ERK 
(1:1000, M5670, Sigma) and α-tubulin (1:1000, T9026, Sigma). Mem-
branes were incubated with horseradish peroxidase-conjugated sec-
ondary antibody was added and proteins detected by chemi 
luminescence system (GE Healthcare Europe GmbH). 
2.4. Cardiac fibroblasts differentiation 
To induce the cardiac fibroblast differentiation into myofibroblast, 
the cells were plated on glass coverslips with Fibroblast Medium-2 
(P60108–2, Innoprot, Derio, Spain). After 24 h in serum depleted 
media, cells were preincubated with VCE-004.8 for 1 h and stimulated 
with TGFβ1 (10 ng/ml) or Ang II for another 2 or 48 h. Coverslips were 
washed with PBS, fixed with methanol: acetone (1:1) and non-specific 
binding reduced by blocking at room temperature for 1 h with 5% 
BSA and 0.1% Triton X-100 in PBS. They were then incubated with the 
primary antibodies overnight at 1:100 dilution. Ki67 antibody was 
purchased from Abcam (ab15580) and anti-α-Smooth Muscle Actin from 
Thermo Fischer (#53–9760–80). Coverslips were mounted using Vec-
tashield Antifade Mounting Medium with DAPI (H-1200, Vector Labo-
ratories, Burlingame, Ca, USA) and images obtained using a spectral 
confocal laser-scanning microscope LSM710 (Zeiss, Jena, Germany) 
with a 25 × /0.8 Plan-Apochromat oil immersion lens. Images were 
quantified in 10–15 randomly chosen fields using ImageJ software (rsb. 
info.nih.gov/ ij/). 
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2.5. Animals studies 
Eight-week-old male C57-BL/6 mice were purchased from Janvier 
Labs (Cedex, France) and housed with free access to standard food and 
water under controlled conditions (temperature 20 ◦C (± 2 ◦C), 40–50% 
relative humidity and 12 h light/dark cycle). All experiments were 
performed in accordance with European Union guideline and approved 
by the Animal Research Ethic Committee of the Córdoba University (23/ 
03/2018/034). Mice were anesthetized using isoflurane and subcu-
taneous infusion of Ang II using ALZET® osmotic pump (Model #2004, 
Charles River, Barcelona, Spain) implanted beneath the midscapular 
loose skin, delivering Ang II (A9525, Sigma, Madrid, Spain) at 1000 ng 
kg− 1 min− 1 in the case of the preventive model, and at 500 ng kg− 1 
min− 1 for the therapeutic model. Pumps were left in place for 14 or 28 
days in the preventive or therapeutic model, respectively (Supplemen-
tary Figure 1A). In the preventive model, starting one day before of the 
pump implantation, EHP-101 (5, 10 and 20 mg/Kg), Losartan (0.6 g/L) 
or AjA (5 mg/Kg) were administrated daily by oral gavage. In the 
therapeutic model, Ang II was infused for four weeks and the treatments, 
EHP-101 (20 mg/Kg) and Losartan (0.6 g/L) were administered orally 
daily during the last two weeks of Ang II infusion (Supplementary 
Figure 1B). Mice were euthanized by cervical dislocation and skin, heart, 
aorta, lung and kidneys were removed, processed for histological ex-
amination or frozen for further analysis. 
2.6. Histological and immunohistochemistry analysis 
Tissue Section (5 μm-thick) were embedded in paraffin. The left 
ventricle sections were stained with Sirius red/ Fast green staining 
(Sigma-Aldrich, Madrid, Spain). First, the sections were incubated in 
0.04% Fast Green for 15 min, washed with distilled water, then incu-
bated in 0.1% Fast Green and 0.04% Sirius Red in saturated picric acid 
for 30 min. For the aorta, kidneys and skin, the sections were stained 
with picrosirius red (Sigma-Aldrich, Madrid, Spain). Tissues were 
incubated in 0.1% Sirius Red in saturated picric acid for 60 min for 
collagen identification. Lung sections were stained with Masson’s tri-
chrome (Merck Millipore, Darmstadt, Germany). To analyze the level of 
fibrosis in lung samples the Ashcroft score was used as previously 
described [26,27,30]. The sections were then dehydrated and mounted 
with Eukitt Mounting Medium (Sigma-Aldrich, Madrid, Spain). Three to 
four random fields of each tissue section were photographed using a 
Leica DFC420c camera by standard brightfield microscopy and evalu-
ated using Fiji software (rsb.info.nih.gov/ij/). For immunohistochem-
istry, heart sections (left ventricle; 5 µm-thick) were deparaffinized and 
boiled in sodium citrate buffer for 10 min (10 mM, pH 6.0) for antigen 
retrieval. Next, incubated three times for 10 min in a Phosphate Buffer 
Saline (PBS) washing buffer containing 0.1% Tween and incubated 
overnight at 4 ◦C with the following antibodies: for immunohisto-
chemical detection of TNC (an extracellular matrix protein involved in 
fibrosis development), anti-TNC antibodies (1:100, #MAB2138, RD 
system, Minneapolis, MN, USA), for T-lymphocyte and macrophage 
infiltration, anti-CD3 antibodies (1:50, SC-20047, Santa Cruz Biotech-
nology) or anti-F4/80 antibodies (1:50, #MCA497, Bio Rad Labora-
tories, Hercules, CA, USA), respectively. The slides were incubated with 
the appropriate biotin-conjugated secondary antibody for 1 h at room 
temperature: goat anti-rat (BP-9400, Vector Laboratories, Burlingame, 
CA, USA) for anti-TNC anti-F4/80 and goat anti-mouse (21538, 
Merck-Millipore) for anti-CD3. Negative controls were incubated only 
with PBS. Reaction products were detected by avidin-biotin-peroxidase 
(Vector Laboratories), the color reaction was developed with DAB (3,3′
diaminobenzidine) chromogen (Dako, Santa Clara, CA, USA), subse-
quent counterstaining with haematoxylin (Sigma-Aldrich) and 
mounting with Eukitt Mounting Medium (Sigma-Aldrich). Three to four 
random fields were digitized using a Leica DFC420c camera and 
analyzed using Image J software by two independent observers. 
2.7. Confocal analysis 
Sections of heart tissue (5 µm) were deparaffinized with sodium 
citrate buffer, washed three times during 10 min in PBS buffer con-
taining 0.1% Triton X-100 and blocked with 3% BSA. They were then 
incubated with the primary antibodies overnight at 1:100 dilution. Ki67 
antibody was purchased from Abcam (ab15580) and anti-α-Smooth 
Muscle Actin from Thermo Fischer (#53–9760–80). The next day sec-
tions were washed three times during 10 min with a wash buffer and 
incubated (1:100 dilution) in darkness at room temperature during 1 h 
with secondary antibody anti-rabbit Texas Red from Thermo Fischer 
(#A-6399). Finally, sections were mounted using Vectashield Antifade 
Mounting Medium with DAPI and images obtained using a spectral 
confocal laser-scanning microscope LSM710 (Zeiss) with a 63 × Plan- 
Apochromat or 25 × /0.8 Plan-Apochromat oil immersion lens. 
2.8. RT-qPCR 
The total RNA from frozen mouse heart tissue was isolated and pu-
rified using QIAzol lysis reagent (Qiagen, Hilden, Germany) and RNeasy 
mini kit (Qiagen). Cardiac Fibroblasts (5 ×104 cells/cm2) were pre-
incubated with VCE 004.8, stimulated with Ang II for either 2 or 24 h 
and total RNA was extracted using High Pure Isolation Kit (Roche 
Diagnostic, Switzerland). Total RNA (1 μg) was retrotranscribed using 
the iScriptTM cDNA Synthesis Kit (Bio-Rad) and the cDNA analyzed 
using a CFX96 Real-Time PCR Detection System (Bio-Rad) by real-time 
PCR using the iQTM SYBR Green Supermix (Bio-Rad). Human HPRT was 
used for in vitro studies and mouse Gadph or Eef2 housekeeping genes 
were used to standardize the mRNA expression levels in each sample. 
Expression levels were calculated using the 2-ΔΔCt method. Sequences 
of oligonucleotide primers are shown in Table 1. 
2.9. RNA-Seq analyses 
RNA samples isolation was performed from myocardial tissue as 
described above and 300 ng of RNA per sample were used to construct a 
cDNA library capturing mRNA through Oligo-dT beads with polyA tails 
(Illumina TruSeq RNA Library Prep Kit v2, #RS-122–2001). The cDNA 
library was sequenced on an Illumina Hiseq 2500 system, generating 
single end 50 bp reads and obtaining ~30 million reads per sample. 
2.10. RNA-Seq bioinformatic analysis 
Raw reads were pre-processed with fastp (v0.20.0) [31] using a 
trimming window size of 4 bp with a required mean quality of 15 and a 
required total length of 20 bp for a read to pass the filter. Then, reads 
were aligned against the GRCm38 genome (v84) from ENSEMBL with 
HISAT2 (v2.1.0) [32]. The count matrix was obtained from the align-
ments using the corresponding ENSEMBL annotation file with featur-
eCounts (v2.0.0) [33]. Normalization and differential expression 
analyses were performed with edgeR (v3.30.0) [34] excluding genes 
with less than 15 counts across all samples. Functional analysis was then 
performed through a gene set enrichment analysis with the fgsea 
package (v1.14.0), ranking genes by the edgeR estimated log trans-
formed fold change and using the functional categories defined by 
MSigDb hallmarks for Mus musculus (V7.0) [35]. 
2.11. Accession numbers 
Raw reads and the count matrix are available at the Gene Expression 
Omnibus (GEO) web site (https://www.ncbi.nlm.nih.gov/geo) using 
accession number GSE151466. 
2.12. Statistical analysis 
Statistical analyses were performed using GraphPad Prism version 
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8.00 (GraphPad, San Diego, CA, U.S.A.). Data from the in vivo experi-
ments are expressed as median ± interquartile as the mean, tested for 
normal distribution using Shapiro-Wilk normality test and analyzed 
using one-way ANOVA followed by Bonferronís post hoc test. Kruskall- 
Wallis followed by Dunńs post-hoc test was used to calculate signifi-
cant differences with data not normally distributed. P < 0.05 was set as 
minimal statistical significance. 
3. Results 
3.1. Effect of VCE-004.8 and Losartan on angiotensin II-induced cardiac 
myofibroblast differentiation and signalling 
The profibrotic activity of Ang II on cardiac fibroblasts in vitro and in 
vivo has been extensively documented [6,12]. To study myofibroblast 
differentiation in vitro, immortalized cardiac fibroblasts (hICF) were 
stained with for α-SMA expression, a specific marker for myofibroblasts 
differentiation. As shown in Fig. 1A, both TGF-β and Ang II induced 
α-SMA protein expression in cultured hICF and pretreatment with 
VCE-004.8 (5 μM) decreased α-SMA expression. The differentiation to 
myofibroblast was associated with morphological changes of cellular 
hypertrophy. We observed cell shape variations from spindle-shaped 
and they exhibited a dendritic morphology compared to cells treated 
with Ang II or TGFβ, which were more spread, hallmark of myofibroblast 
differentiation. To further study the effect of VCE-004.8 on Ang II 
signaling pathways in hICF, we analyzed ERK1 + 2 and NFAT activation, 
two pathways activated by Ang-II [36]. VCE-004.8, as well as Losartan, 
inhibited both Ang II-induced ERK1 + 2 phosphorylation and NF-AT 
activation in hICF (Fig. 1B and C). We also found that VCE-004.8 
inhibited the mRNA expression of IL1β, IL6, Col1A2 and CCL2, 
induced by Ang II or TGFβ in hICF cells (Fig. 1D). 
3.2. EHP 101 and Ajulemic acid prevented interstitial and perivascular 
myocardial collagen deposition induced by Ang-II infusion 
In C57-BL/6 mice, Ang-II infusion for two weeks significantly 
increased collagen deposition in the left ventricle, particularly in the 
interstitial and perivascular areas. Treatment with EHP-101 initiated at 
the same time as Ang II infusion (preventive model) attenuated inter-
stitial cardiac fibrosis as well as perivascular fibrosis in a dose- 
dependent manner and similar results were observed in the heart of 
mice administered with Losartan (0.6 gr/L). AjA, another synthetic 
cannabinoid targeting CB2R and PPARγ [28,37] also prevented inter-
stitial and perivascular fibrosis although with lower efficacy compared 
to EHP-101. To analyze total collagen, Picrosirius red staining was used 
(Fig. 2A and B). 
3.3. EHP-101 ameliorated Ang II-induced aortic, kidney and skin fibrosis 
in a preventive model of fibrosis 
It has been described that Ang II induces fibrosis on internal organs 
and skin [9–12]. Thus, we performed histochemical studies in order to 
investigate the effects of EHP-101 in the preventive model of Ang 
II-induced organ fibrosis. In aortic vessel, the collagen content in the 
adventitial layer was increased in mice infused with Ang II (0.6 units vs 
0.375 units in control group) and the media layer thickness was signif-
icantly reduced by both EHP-101 treatment (0.425 units) or Losartan 
(0.38 units) (Fig. 3A). The area between the external elastic lamina and 
the tunica externa is called the adventitia area, which is the outermost 
layer of the vessel. We examined also the effect of the treatments on 
renal fibrosis by Massońs trichrome and picrosirius red staining. Kidneys 
of mice infused with PBS showed low levels of collagen deposition 
(6.94% collagen area and 2.69% fibrotic area) (Fig. 3B). However, 
collagen accumulation and augmentation of fibrotic area in the inter-
stitial sites was clearly detected in kidneys of mice subjected to Ang-II 
infusion (29.11% collagen area and 18.22% fibrotic area). Collagen 
deposition and fibrotic area were significantly reduced by treatment 
with either EHP-101 (3.78% collagen area and 6.43% fibrotic area) or 
Losartan (0.6 g/L) (11.97% and 8.08% collagen and fibrotic area 
respectively) (Fig. 3B). 
We have previously shown that EHP-101 alleviates dermal fibrosis 
through PPARγ and CB2R receptor-dependent pathways in a mice model 
of SSc [26,27]. Thus, we investigated the effect of oral EHP-101 in 
dermal fibrosis induced by Ang II. Picrosirius red staining indicated that 
collagen fibers were more closely packed in Ang II infused mice 
(37.95%) compared with control saline infused mice (20.69%), reflect-
ing increased collagen and extracellular matrix deposition (Fig. 3C). The 
deposition of collagen fibers was attenuated with either EHP-101 
(28.17%) (20 mg/Kg) or Losartan (0.6 g/L) (19.03%) treatments. 
3.4. Pharmaco-transcriptomic signature of EHP-101 and Losartan in 
cardiac tissue 
In order to obtain a global perspective of the effect of EHP-101 on 
cardiac fibrosis, we performed a detailed study of the tissue tran-
scriptome changes in response to Ang II, Ang II +EHP-101 and Ang II +
Losartan. Thus, we used a mRNA-Seq approach to obtain a total of 
16,163 genes with more than 15 counts across all samples, which were 
considered for further analyses. Following the differential expression 
analysis with edgeR, the functional analysis revealed complementary 
signature for transcriptomic hallmarks related with the inflammatory 
and fibrotic processes, which were up-regulated in response to Ang II 
and down-regulated with both treatments (EHP-101 and Losartan). 
Some examples can be found in the Figs. 4A and 5A, as “Inflammatory 
response” and “Epithelial mesenchymal transition” (fgsea adjusted P 
value < 0.05). Then, to study those changes at the gene level, we used 
the leading-edge analysis to determine which features were driving the 
Table 1 
Sequences of mouse (m) and human (h) RT-PCR primers.  
Gene Forward Reverse 
mIl-6 5 ́ -GAACAACGATGATGCACTTGC-3 ́ 5 ́ -TCCAGGTAGCTATGGTACTCC-3 
mI-1β 5 ́ -CTCCACCTCAATGGACAGAA-3 ́ 5 ́ -GCCGTCTTTCATTACACAGG-3 ́
mTnc 5 ́ -ATCCCTTCATCAGCAGTCCA-3 ́ 5 ́ -GCATCCGTACCAAAACCATC-3 ́
mCdk1 5 ́ -CAGAGATTGACCAGCTCTT-3 ́ 5 ́ -GAAAGGTGTTCTTGTAGTCC-3 ́
mTop2a 5′-CGGAATGACAAGCGAGAAGTAA-3′ 5′-GCATTGTAAAGATGTATCGTGGAC-3′
mMki67 5 ́ -AATCCAACTCAAGTAAACGGGG-3 ́ 5 ́ -TTGGCTTGCTTCCATCCTCA-3 ́
mGapdh 5 ́ -TGGCAAAGTGGAGATTGTTGCC-3 ́ 5 ́ -AAGATGGTGATGGGCTTCCCG-3 ́
mEef2 5 ́ -TGTCAGTCATCGCCCATGTG-3 ́ 5 ́ -CATCCTTGCGAGTGTCAGTGA-3 ́
hIL1β 5 ́ -GACCTTCCAGGATGAGGACA-3 ́ 5 ́ -AGCTCATATGGGTCCGACAG-3 ́
hIL6 5 ́ -GGTACATCCTCGACGTGTCT-3 ́ 5 ́ -GTGCCTCTTTGCTGCTTTCAC-3 ́
hCOL1A2A 5 ́ -CCGTGCTTCTCAGAAGACAG-3 ́ 5 ́ -CTTGCCCCATTCATTCATCA-3 ́
hCCL2 5 ́ - CCCCAGTCACCTGCTGTTAT-3 ́ 5 ́ -TGG AAT CCT GAA CCC ACT TC-3 ́
hHPRT 5 ́ -ATGGGAGGCCATCACATTGT-3 ́ 5 ́ -ATGTAATCCAGCAGGTCAGCAA-3 ́
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Fig. 1. VCE-004.8 prevents cardiac fibroblasts differentiation into myofibroblasts. A. Representative images of cardiac fibroblasts differentiation into myo-
fibroblasts induced with Ang II or TGFβ and treated with VCE-004.8. B. Western blot images showing inhibition of p-ERK after treatment with VCE-004.8 or Losartan. 
C. Effect of VCE-004.8 on NF-AT transcriptional activity. hICH cells were transfected with a GAL4-NFAT expression plasmid plus a GAL4-Luc reporter plasmid. Cells 
were preincubated with the VCE-004.8 or Losartan for 20 min and stimulated with Ang II (1 μM) for 6 h. Cells were lysed for luciferase activity. Results are presented 
as the percentage of luciferase activity relative to control (100% for Ang II treatment). D. The mRNA expression of genes (IL1β, IL6, COL1A2 and CCL2) was 
quantified by qPCR and normalized to the levels of HPRT. Cells were incubated with VCE-004.8 for 1 h following Ang II or TGF-β for 2 or 24 h. Data represent the 
mean ± SEM, and significance was determined by Kruskall-Wallis followed by Dunńs post-hoc test. ***p < 0.001, **p < 0.01 and *p < 0.05 vs control; 
###p< 0.001, ##p < 0.01 and p < 0.05vs Ang II. 
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observed results. Hence, we obtained three lists of genes for the “In-
flammatory response” and “Epithelial mesenchymal transition” hall-
marks, one per contrast, which showed an overlap of 52 and 64 genes, 
respectively (Fig. 5B). The expression values for the first 25 leading edge 
genes in response to Ang II are shown on the Fig. 4B. In order to confirm 
these results, the expression of selected genes connected to inflamma-
tion and fibrosis was studied by RT-qPCR. As expected, Ang II-infused 
mice showed significantly higher expression levels of Tnc, Il6 and Il1β 
in cardiac left ventricle compared to the control group. Mice treated 
with either EHP-101 or Losartan showed a significantly reduced up- 
regulation (Fig. 4C). 
To confirm the inhibitory effects of EHP-101 on inflammation and 
fibrosis, we analysed the infiltration of T cells (CD3+ cells) and macro-
phages (F4/80+ cells) in the heart left ventricle. As depicted in Fig. 4D, 
Fig. 2. EHP-101 prevents cardiac fibrosis. A. Representative images of picrosirius red/green fast stained left ventricle sections of the preventive model, interstitial 
and perivascular area showing collagen accumulation in purple (upper and middle and bottom panel respectively). B. Quantification of collagen accumulation 
interstitial and perivascular in heart. In order to normalize for vessel size, a ratio of adventitial area/vessel area was calculated and represent the normalized 
perivascular fibrotic area. Values are expressed as median ± interquartile range with statistical comparison. For all these area measurements, three to four sections 
from 3 to 7 mice per group were analyzed. Ang II–treated wild-type mice and all other conditions. ***p < 0.001 vs control group; ###p < 0.001, vs Ang II group. 
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Fig. 3. EHP-101 treatment prevents increase aortic media thickness, renal and skin fibrosis induced by Ang II. A. Representative images of aortic sections for 
Sirius red in preventive model (left panel) and the quantification of respective measurements on aorta sections (right panel). Blue arrows indicate aortic media B. 
Representative photomicrographs of renal tissue from Ang II mouse preventive model stained with picrosirius (upper left panel) red and Massońs trichome (bottom 
left panel) and representative results for quantification of respective measurements of collagen area and fibrotic area respectively in kidney (right panel). C. 
Representative photomicrographs of dermal tissue stained with picrosirius red (left panel) and results for quantification of respective measurements of collagen area 
in skin. Data are expressed as median ± interquartile range with statistical comparison between Ang II–treated wild-type mice and all other conditions. For all these 
area measurements, three to four sections from three to five mice per group were analyzed. ***p < 0.001 vs control group; ###p < 0.001, ##p < 0.01 vs Ang 
II group. 
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we found an increase of infiltrated T cells and macrophages in Ang-II 
infused group in comparison with control saline infused mice. The 
number of T cells and macrophages was reduced by the oral treatment 
with both EHP-101 and Losartan. Moreover, immunohistochemistry 
confirmed that cardiac expression of TNC was absent in the heart of 
animals infused with saline and significantly increased in Ang II 
challenged mice. However, oral administration of EHP-101 reduced Ang 
II–induced TNC protein expression to levels similar to those of Losartan 
(Fig. 4D and E). 
In addition to this complementary signature for hallmarks related 
with inflammation and fibrosis, the mRNA-Seq analysis also revealed a 
group of transcriptomic alterations which occurred only in response to 
Fig. 4. EHP-101 alleviated inflammation and fibrotic markers in heart. A. Gene set enrichment analysis results. The dot plot shows the selected significantly 
altered hallmarks (Y axis) per contrasts (X axis). The arrow shape, size and color indicate the direction, significance and normalized enrichment score for each result, 
respectively. Only results with an adjusted P value <0.05 are shown. B. Gene expression values for the top 25 leading edge genes within the hallmarks “Inflammatory 
response” and “Epithelial mesenchymal transition” at the Ang II vs Control contrast. The heatmap color indicates the mean of the scaled expression values after 
normalization. C. Gene expression of profibrotic and pro-inflammatory genes including Il6, Il1β, and Tnc were measured by RT-qPCR. Expression levels were 
calculated using the 2-ΔΔCt method. Values are expressed as mea ± SEM for three animals per group. ***p < 0.001 vs control group ###p< 0.001, #p < 0.05vs Ang 
II group. D. Representative images of CD3 + T-lymphocyte infiltration, F4/ 80 + macrophages and Tenascin C (TNC) in the heart detected by immunostaining. E. 
Representative results quantified and expressed as CD3 (+) cells/area, F4/80(+) cells/area and TNC percentage of area/image. Results are expressed as 
median ± interquartile range with statistical comparison between Ang II–treated wild-type mice and all other conditions. For all these area measurements, three to 
four sections five to seven mice per group were analyzed. ***p < 0.001 vs control group; ###p < 0.001 vs Ang II group. 
Fig. 5. Gene expression values for all the genes included in the “Inflammatory response”, “Epithelial mesenchymal transition” and “E2F targets” hallmarks. The 
heatmap color indicates the scaled expression values after normalization. B. Overlap between the leading-edge genes for each contrast on the “Inflammatory 
response” and “Epithelial mesenchymal transition” hallmarks, being A) Ang II vs Control, B) Ang II + EHP-101 vs Ang II and C) Ang II + Los vs Ang II. 
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EHP-101 treatment. The top 10 altered hallmarks for the Ang II + EHP- 
101 vs Ang II contrast are shown in the Fig. 6A. The down-regulation of 
the “E2F targets” with EHP-101 is important, given the regulatory role of 
this family of transcription factors in the cardiac fibrotic process [38]. As 
previously done with the other hallmarks, the leading-edge analysis was 
used to determine which genes were responsible for this result. In 
Fig. 6B, we show the expression values for the first 25 leading edge genes 
on this functional category for the Ang II + EHP-101 vs Ang II. To further 
confirm this result, we evaluated the expression level of genes related to 
E2F targets hallmark such as Cyclin-dependent kinase 1 (Cdk1), DNA 
Topoisomerase II Alpha (Top2a) and Marker of Proliferation Ki67 
(Mki67). Quantitative real-time polymerase chain reaction revealed a 
reduction on gene expression levels in the EHP-101 administered group 
as compared with Ang II infused mice (Fig. 6C). Ki67 expression was also 
induced by Ang II in hICF and prevented by the pretreatment with 
VCE-004.8 (Fig. 6D). Moreover, and consistent with the antifibrotic ef-
fect of EHP-101, there was a significant reduction of expression of 
α-SMA in EHP-101-treated mice in comparison with Ang-II-infused mice 
(Fig. 6E). In addition, Mki67 expression changes were confirmed at the 
protein level by immunofluorescent staining for Mki67. The number of 
Ki67+ cells were increased in Ang-II infused mice and significantly 
reduced by EHP-101 but not by Losartan (Fig. 6F). 
3.5. EHP-101 alleviated Ang II-induced perivascular cardiac, aortic, 
kidney and lung fibrosis and cardiac immune cells infiltration in the 
therapeutic model of fibrosis 
Next, we evaluated the potential therapeutic effect of EHP-101 on 
fibrosis. Mice were infused with Ang II (500 ng Kg− 1 min− 1) for four 
weeks and EHP-101 treatment was administered daily only for the last 
two weeks. As shown in Fig. 7A, the collagen accumulation on inter-
stitial and perivascular myocardial determined by picrosirius red 
staining was augmented in mice infused with Ang II (32.77% area and 
perivascular ratio of 3.3) in comparison to control mice infused with 
saline (16.8% area and perivascular ratio of 0.34). Collagen deposition 
was significantly attenuated in mice treated with either EHP-101 
(20 mg/Kg) (13.53% area and perivascular ratio of 1.28) or Losartan 
(0.6 g/L) (16.2% area and perivascular ratio of 1.26) compared with the 
Ang II group. Next, we analyzed the infiltrated T cells (CD3+) and 
macrophages (F4/80+) in the left ventricle. Ang II induced a significant 
increase in the number of CD3+ T-lymphocyte infiltration into the heart 
compared to control mice (Fig. 7B), which was significantly reduced by 
either EHP-101 or Losartan treatment. Similarly, macrophage infiltra-
tion into the left ventricle was extensively observed in both interstitial 
and perivascular regions in Ang II–infused mice and reduced by both 
treatments (Fig. 7C). 
Furthermore, Ang II infusion for four weeks increased aortic medial 
thickness mediated by collagen deposition (approximately 2-fold) in 
comparison with control mice (Fig. 8A), which was attenuated by oral 
EHP-101 (1.3-fold) and by Losartan (1.26-fold) treatments. The anti-
fibrotic effect of EHP-101 was also evaluated in the kidneys. Kidneys of 
mice infused with Ang II for 4 weeks showed an increase in collagen 
accumulation (27.37%) compared to mice infused with saline (15.3%). 
Kidney fibrosis in Ang II-challenged mice was greatly reduced by the 
treatment with EHP-101 (21.06%) but not by Losartan (24.16%) 
(Fig. 8B). 
There is significant evidence that Ang II induces pulmonary fibrosis 
in animal models [10]. Therefore, we explored the therapeutic potential 
of EHP-101 on lung fibrosis. We confirmed that Ang II-infused mice 
developed lung fibrosis in the pulmonary parenchyma, as assessed his-
tologically by Massońs trichrome staining and determined by Ashcroft 
score (from 4.6 to 2.6 score). Both EHP-101 and Losartan significantly 
alleviated lung fibrosis (Fig. 8C). Collectively, our results demonstrate 
that administration of EHP-101 in the therapeutic model reduced Ang 
II–induced fibrosis in several internal organs. 
4. Discussion 
In previous publications, we have shown the development of the 
compound of VCE-004.8, which is a dual agonist for PPARγ/CB2R able 
to inhibit HIF prolyl hydroxylases (PHDs) [25,39]. This is an example of 
how synthetic derivatives from cannabinoids with improved bio-
activities can be used in the field [40]. In this sense, in this work we have 
studied the effect of EHP-101 on preventive and therapeutic models of 
organ fibrosis induced by Ang II. Specifically, EHP-101 was able to 
alleviate cardiac, aortic, lung, kidney and skin fibrosis that paralleled a 
significant reduction in the infiltration of inflammatory cells in the heart 
of Ang II-challenged mice. 
In many fibrotic diseases, tissue inflammation precedes fibrosis and, 
therefore, it is possible that the anti-inflammatory activity of EHP-101, 
mediated through CB2R and PPARγ, may inhibit T-cell and macrophage 
activation [26,27]. Ang II is a potent vasoconstrictor that increases AT1 
receptor expression and promotes fibrosis in the skin and internal organs 
[9–12]. Moreover, this peptide directly activates cells and inflammatory 
signals that trigger the fibrogenesis machinery, promoting proliferation 
of myofibroblasts and accumulation of ECM, such as collagen. [7,12,41]. 
Here, we found that EHP-101 alleviated fibrosis in the internal organs of 
Ang II induced mouse fibrosis models, and that VCE-004.8 may prevent 
AT1 and/or AT2 signalling in cardiac fibroblasts. This mitigation of the 
fibrogenesis could be promoted by the PPARγ ligand action of EHP-101. 
In fact, PPARγ ligands ameliorate fibrogenesis and collagen accumula-
tion, inhibiting skin and organ fibrosis, including cardiac fibrosis [23, 
25–27,42]. We and others have also shown that CB2R agonists exert 
antifibrotic effects on multiple internal organs and the skin [25–27,43]. 
On the other hand, HIF-1α activation, which can be induced by PHDs 
inhibition, has been observed to support wound healing through regu-
lation of inflammation, angiogenesis and vasculogenesis in acute injury 
[44]. Moreover, the HIF-dependent gene, erythropoietin (EPO) gene, 
provides efficient protection against renal fibrosis [45]. The ability of 
VCE-004.8 to inhibit PHDs may also account for its antifibrotic activity 
since it has been shown that conditional ablation of PHD2 in myeloid 
lineage attenuates hypertensive cardiovascular hypertrophy and fibrosis 
[46]. 
In the same sense, in a model of ventricular dysfunction, the treat-
ment with a selective HIF PHD inhibitor (GSK360A) after myocardial 
infarction improves ventricular function [47]. Other studies in mice 
have shown that HIF-1α activation and increased levels of the Vascular 
endothelial growth factor in cardiac tissue reduce cardiac hypertrophy 
and myocardial fibrosis induced by pressure-overload [48]. Interest-
ingly, the efficacy of EHP-101 seemed to be superior to AjA, another 
cannabinoid with dual PPARγ/CB2R agonistic activity, which is the 
active ingredient of Lenabasum®, a drug candidate for the treatment of 
diffuse cutaneous Systemic Sclerosis [49]. Since AjA does not signal 
through the HIF pathway, our results further support the possibility that 
this pathway is importantly involved in the therapeutic effect of 
EHP-101 as suggested previously in a murine model of SS induced by 
bleomycin [27]. Nevertheless, the exact mechanism of action for 
EHP-101 (VCE-004.8) in Ang-II-induced organ fibrosis requires further 
research using genetic or pharmacological models. 
Previous evidence indicates that inflammation is an early event and 
plays a fundamental role in development of cardiac fibrosis [1]. Ang II 
induces infiltration of inflammatory cells in the myocardium, thus 
initiating remodeling and consequently cardiac fibrosis [21,50]. The 
components of inflammation include macrophages and T cells that are 
associated with secretion of cytokines, such as IL1β, IL6 and TGF-β. They 
also include extracellular matrix protein deposition, such as Collagen 
and TNC that are the hallmark for cardiac fibrosis development [50–52]. 
Herein, our results demonstrate that EHP-101 reduces the infiltration of 
inflammatory cells and fibrosis in the left ventricle, in both preventive 
and therapeutic models of Ang-II-induced fibrosis in mice. 
Interestingly, we observed a specific downregulation by EHP-101 of 
a group of genes that are classified as the “E2F targets” hallmark. The 
A. García-Martín et al.                                                                                                                                                                                                                        
Biomedicine & Pharmacotherapy 142 (2021) 112007
11
Fig. 6. Inhibitory effect of EHP-101 on E2F pathway and cardiac myofibroblast. A. Top 10 significant hallmarks at the Ang II + EHP-101 vs Ang II contrast. The 
hallmarks (Y axis) are ordered by their normalized enrichment score (X axis). Only results with an adjusted P value < 0.05 are shown. B. Gene expression values for 
the top 25 leading edge genes on the hallmark “E2F targets” at the Ang II + EHP-101 vs Ang contrast. The heatmap color indicates the mean of the scaled expression 
values after normalization. C. Gene expression on the E2F pathways markers including Cdk1, topoisomerase 2-alpha (Top2a) and Mki67 were measured by RT-qPCR. 
Expression levels were calculated using the 2-ΔΔCt method. Values are expressed as mean- ± SEM for at least seven animals per group. *p < 0.05 vs Ang II group. D. 
Representative images of hICF differentiation into myofibroblasts. Cells were pretreated with VCE-004.8 for 1 h and stimulated with Ang II (1 μM) for 2 h. hICF were 
stained for α-SMA (green), Ki67 (red) and DAPI (blue). E. Immunofluorescence labelling of smooth muscle cells (α-SMA, green fluorescence) in heart. F. Repre-
sentative immunofluorescence images of myofibroblast proliferation in left ventricular section stained with Ki67 (red fluorescence). Cells are marked by yellow 
arrows (left panel). Quantification of number of Ki67-positive cells from 5 to 10 fields per heart (right panel). Four animals from each group were analyzed. Data are 
presented as median ± interquartile range with statistical comparison between Ang II–treated wild-type mice and all other conditions. ***p < 0.001 vs control group; 
###p < 0.001 vs Ang II group. 
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E2F family of transcription factors plays a crucial role in controlling the 
expression of genes involved in cell proliferation, differentiation, and 
apoptosis [53]. A recent study indicated that the modulation of CDK1, a 
known target of the E2F pathway, is involved in G1 checkpoint regu-
lation, which inhibits the proliferation of cardiac fibroblast, thus 
exerting a protective effect on cardiac fibrosis [54]. Moreover, the 
expression and activity of E2F molecules have been detected in the 
development of myocyte hypertrophy and blocking E2F function in-
hibits the death of cardiomyocytes [55]. It is likely that EHP-101 
through the E2F pathway could ameliorate the proliferation of myofi-
broblasts and the hypertrophy of cardiomyocytes induced by Ang II 
infusion. 
The Ang II signal transduction process is known to produce both 
inflammation and fibrosis, by promoting the endoplasmic reticulum 
stress and activating the nuclear factor-κB and TGF-β-related signaling 
pathways [8]. Our transcriptomic analysis has shown that both the 
EHP-101 and Losartan treatments were able to normalize the expression 
of some genes such as Il1β, Il1α or Il6, reflecting the activity of infiltrated 
T cells and macrophages in the cardiac tissue [50]. On the other hand, 
the diminished expression levels of genes such as Tnc [51], Collagen 
(Col)1a2 and Fibronectin1 (Fn1) would be the consequence of a reduced 
myofibroblast activity [51,52]. Such myofibroblasts are responsible for 
Fig. 7. Therapeutic EHP-101 effect on cardiac fibrosis. A. Representative images of picrosirius red/green fast stained left ventricle sections, interstitial and 
perivascular area showing collagen accumulation in purple (left panel) and their quantification of collagen accumulation interstitial and perivascular in heart (right 
panel). The ratio of adventitial area/vessel area was calculated and represent the normalized perivascular fibrotic area Values are expressed as 
median ± interquartile range with statistical comparison. B. Representative images of CD3 + T-lymphocyte infiltration in cardiac tissue detected by immunostaining 
and quantified results expressed as CD3 (+) cells/area (right panel). C. Representative images of F4/80 + macrophages in the heart detected by immunostaining and 
quantified results expressed as F4/80(+) cells/area (right panel). For all these area measurements, three to four sections from a sample from four to eight mice per 
group were analyzed ***p < 0.001 vs control group; ###p < 0.001, ##p < 0.01 vs Ang II group. 
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“executing” the TGF-β driven fibrosis. Of note is the similarity between 
the transcriptomic signatures observed in response to EHP-101 and 
Losartan, taking into account the different mechanism of action of both 
compounds. The main limitation of this study is that we do not have 
demonstrated the direct participation of E2F targets genes in the efficacy 
of EHP-101 on Ang-II-induced cardiac and other organs fibrosis and 
genetic experiments are needed to validate this novel mechanism of 
action. 
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Officer of Emerald Health Pharmaceuticals. Giovanni Appendino is a 
member of the Scientific Advisory Board of Emerald Health 
Pharmaceuticals. 
Author contributions 
AGM, CN and MEP conducted in vivo and in vitro experiments; MGR 
performed the bioinformatic analysis; DC and GA synthesized Ajulemic 
acid. AGM and EM managed, designed the overall study and wrote the 
manuscript. All the authors approved the final manuscript. 
Appendix A. Supporting information 
Supplementary data associated with this article can be found in the 
online version at doi:10.1016/j.biopha.2021.112007. 
References 
[1] L.A. Murtha, M.J. Schuliga, N.S. Mabotuwana, S.A. Hardy, D.W. Waters, J. 
K. Burgess, D.A. Knight, A.J. Boyle, The processes and mechanisms of cardiac and 
pulmonary fibrosis, Front Physiol. 8 (2017) 777, https://doi.org/10.3389/ 
fphys.2017.00777. 
[2] M. Writing Group, D. Mozaffarian, E.J. Benjamin, A.S. Go, D.K. Arnett, M.J. Blaha, 
M. Cushman, S.R. Das, S. de Ferranti, J.P. Despres, H.J. Fullerton, V.J. Howard, M. 
D. Huffman, C.R. Isasi, M.C. Jimenez, S.E. Judd, B.M. Kissela, J.H. Lichtman, L. 
D. Lisabeth, S. Liu, R.H. Mackey, D.J. Magid, D.K. McGuire, E.R. Mohler 3rd, C. 
S. Moy, P. Muntner, M.E. Mussolino, K. Nasir, R.W. Neumar, G. Nichol, 
L. Palaniappan, D.K. Pandey, M.J. Reeves, C.J. Rodriguez, W. Rosamond, P. 
D. Sorlie, J. Stein, A. Towfighi, T.N. Turan, S.S. Virani, D. Woo, R.W. Yeh, M. 
B. Turner, C. American Heart Association Statistics, S. Stroke Statistics, Heart 
Disease and Stroke Statistics-2016 update: a report from the American Heart 
Association, Circulation 133 (4) (2016) e38–e360, https://doi.org/10.1161/ 
CIR.0000000000000350. 
[3] C. Jellis, J. Martin, J. Narula, T.H. Marwick, Assessment of nonischemic 
myocardial fibrosis, J. Am. Coll. Cardiol. 56 (2) (2010) 89–97, https://doi.org/ 
10.1016/j.jacc.2010.02.047. 
[4] M. Disertori, M. Mase, F. Ravelli, Myocardial fibrosis predicts ventricular 
tachyarrhythmias, Trends Cardiovasc Med 27 (5) (2017) 363–372, https://doi.org/ 
10.1016/j.tcm.2017.01.011. 
[5] B.C. Berk, K. Fujiwara, S. Lehoux, ECM remodeling in hypertensive heart disease, 
J. Clin. Investig. 117 (3) (2007) 568–575, https://doi.org/10.1172/JCI31044. 
[6] M.J. Ivey, M.D. Tallquist, Defining the cardiac fibroblast, Circ. J. 80 (11) (2016) 
2269–2276, https://doi.org/10.1253/circj.CJ-16-1003. 
[7] R.E. Schmieder, K.F. Hilgers, M.P. Schlaich, B.M. Schmidt, Renin-angiotensin 
system and cardiovascular risk, Lancet 369 (9568) (2007) 1208–1219, https://doi. 
org/10.1016/S0140-6736(07)60242-6. 
[8] S.J. Forrester, G.W. Booz, C.D. Sigmund, T.M. Coffman, T. Kawai, V. Rizzo, 
R. Scalia, S. Eguchi, Angiotensin II signal transduction: an update on mechanisms 
of physiology and pathophysiology, Physiol. Rev. 98 (3) (2018) 1627–1738, 
https://doi.org/10.1152/physrev.00038.2017. 
[9] U.M. Steckelings, T. Wollschlager, J. Peters, B.M. Henz, B. Hermes, M. Artuc, 
Human skin: source of and target organ for angiotensin II, Exp. Dermatol. 13 (3) 
(2004) 148–154, https://doi.org/10.1111/j.0906-6705.2004.0139.x. 
[10] J. Wang, L. Chen, B. Chen, A. Meliton, S.Q. Liu, Y. Shi, T. Liu, D.K. Deb, J. Solway, 
Y.C. Li, Chronic activation of the renin-angiotensin system induces lung fibrosis, 
Sci. Rep. 5 (2015) 15561, https://doi.org/10.1038/srep15561. 
[11] S.A. Mezzano, M. Ruiz-Ortega, J. Egido, Angiotensin II and renal fibrosis, 
Hypertension 38 (3 Pt 2) (2001) 635–638, https://doi.org/10.1161/ 
hy09t1.094234. 
[12] H.H. Sigusch, S.E. Campbell, K.T. Weber, Angiotensin II-induced myocardial 
fibrosis in rats: role of nitric oxide, prostaglandins and bradykinin, Cardiovasc Res 
31 (4) (1996) 546–554. 
[13] J. Sadoshima, Cytokine actions of angiotensin II, Circ. Res 86 (12) (2000) 
1187–1189, https://doi.org/10.1161/01.res.86.12.1187. 
[14] J.R. Gomolak, S.P. Didion, Angiotensin II-induced endothelial dysfunction is 
temporally linked with increases in interleukin-6 and vascular macrophage 
accumulation, Front Physiol. 5 (2014) 396, https://doi.org/10.3389/ 
fphys.2014.00396. 
[15] S. Kim, H. Iwao, Molecular and cellular mechanisms of angiotensin II-mediated 
cardiovascular and renal diseases, Pharm. Rev. 52 (1) (2000) 11–34. 
[16] M.J. Sopel, N.L. Rosin, T.D. Lee, J.F. Legare, Myocardial fibrosis in response to 
Angiotensin II is preceded by the recruitment of mesenchymal progenitor cells, 
Lab. Investig. 91 (4) (2011) 565–578, https://doi.org/10.1038/ 
labinvest.2010.190. 
[17] A.R. Brasier, A. Recinos 3rd, M.S. Eledrisi, Vascular inflammation and the renin- 
angiotensin system, Arterioscler. Thromb. Vasc. Biol. 22 (8) (2002) 1257–1266, 
https://doi.org/10.1161/01.atv.0000021412.56621.a2. 
[18] Q. Zhao, M. Ishibashi, K. Hiasa, C. Tan, A. Takeshita, K. Egashira, Essential role of 
vascular endothelial growth factor in angiotensin II-induced vascular inflammation 
and remodeling, Hypertension 44 (3) (2004) 264–270, https://doi.org/10.1161/ 
01.HYP.0000138688.78906.6b. 
[19] S.L. Lai, R. Marin-Juez, D.Y.R. Stainier, Immune responses in cardiac repair and 
regeneration: a comparative point of view, Cell Mol. Life Sci. 76 (7) (2019) 
1365–1380, https://doi.org/10.1007/s00018-018-2995-5. 
[20] N.G. Frangogiannis, C.W. Smith, M.L. Entman, The inflammatory response in 
myocardial infarction, Cardiovasc. Res. 53 (1) (2002) 31–47, https://doi.org/ 
10.1016/s0008-6363(01)00434-5. 
[21] F.C. Simoes, T.J. Cahill, A. Kenyon, D. Gavriouchkina, J.M. Vieira, X. Sun, 
D. Pezzolla, C. Ravaud, E. Masmanian, M. Weinberger, S. Mayes, M.E. Lemieux, D. 
N. Barnette, M. Gunadasa-Rohling, R.M. Williams, D.R. Greaves, L.A. Trinh, S. 
E. Fraser, S.L. Dallas, R.P. Choudhury, T. Sauka-Spengler, P.R. Riley, Macrophages 
directly contribute collagen to scar formation during zebrafish heart regeneration 
and mouse heart repair, Nat. Commun. 11 (1) (2020) 600, https://doi.org/ 
10.1038/s41467-019-14263-2. 
[22] E. Caglayan, B. Stauber, A.R. Collins, C.J. Lyon, F. Yin, J. Liu, S. Rosenkranz, 
E. Erdmann, L.E. Peterson, R.S. Ross, R.K. Tangirala, W.A. Hsueh, Differential roles 
of cardiomyocyte and macrophage peroxisome proliferator-activated receptor 
gamma in cardiac fibrosis, Diabetes 57 (9) (2008) 2470–2479, https://doi.org/ 
10.2337/db07-0924. 
[23] M. Asakawa, H. Takano, T. Nagai, H. Uozumi, H. Hasegawa, N. Kubota, T. Saito, 
Y. Masuda, T. Kadowaki, I. Komuro, Peroxisome proliferator-activated receptor 
gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in 
vivo, Circulation 105 (10) (2002) 1240–1246, https://doi.org/10.1161/ 
hc1002.105225. 
[24] S. Marquart, P. Zerr, A. Akhmetshina, K. Palumbo, N. Reich, M. Tomcik, A. Horn, 
C. Dees, M. Engel, J. Zwerina, O. Distler, G. Schett, J.H. Distler, Inactivation of the 
cannabinoid receptor CB1 prevents leukocyte infiltration and experimental 
fibrosis, Arthritis Rheum. 62 (11) (2010) 3467–3476, https://doi.org/10.1002/ 
art.27642. 
[25] C. del Río, C. Navarrete, J.A. Collado, M.L. Bellido, M. Gómez-Cañas, M.R. Pazos, 
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